An active-site mutation (Gly633 .fwdarw. Arg) of dipeptidyl peptidase IV causes its retention and rapid degradation in the endoplasmic reticulum

Biochemistry ◽  
1992 ◽  
Vol 31 (47) ◽  
pp. 11921-11927 ◽  
Author(s):  
Emiko Tsuji ◽  
Yoshio Misumi ◽  
Toshiyuki Fujiwara ◽  
Noboru Takami ◽  
Shigenori Ogata ◽  
...  
2005 ◽  
Vol 280 (15) ◽  
pp. 14911-14917 ◽  
Author(s):  
Wilhelm Andreas Weihofen ◽  
Jianguo Liu ◽  
Werner Reutter ◽  
Wolfram Saenger ◽  
Hua Fan

2021 ◽  
Author(s):  
Ritian Jin ◽  
Haowei Ren ◽  
Minhe Liao ◽  
Jiaqi Shang ◽  
Dangfeng Wang ◽  
...  

The peptide VLATSGPG (VLA) is known to inhibit dipeptidyl peptidase IV (DPP-IV), although its mechanism in relieving endoplasmic reticulum (ER) stress is unclear. In this study, we found that treating...


2013 ◽  
Vol 434 (2) ◽  
pp. 191-196 ◽  
Author(s):  
Mika Nabeno ◽  
Fumihiko Akahoshi ◽  
Hiroyuki Kishida ◽  
Ikuko Miyaguchi ◽  
Yoshihito Tanaka ◽  
...  

2000 ◽  
Vol 192 (9) ◽  
pp. 1223-1236 ◽  
Author(s):  
Eva Richard ◽  
Francisco X. Arredondo-Vega ◽  
Ines Santisteban ◽  
Susan J. Kelly ◽  
Dhavalkumar D. Patel ◽  
...  

Human, but not murine, adenosine deaminase (ADA) forms a complex with the cell membrane protein CD26/dipeptidyl peptidase IV. CD26-bound ADA has been postulated to regulate extracellular adenosine levels and to modulate the costimulatory function of CD26 on T lymphocytes. Absence of ADA–CD26 binding has been implicated in causing severe combined immunodeficiency due to ADA deficiency. Using human–mouse ADA hybrids and ADA point mutants, we have localized the amino acids critical for CD26 binding to the helical segment 126–143. Arg142 in human ADA and Gln142 in mouse ADA largely determine the capacity to bind CD26. Recombinant human ADA bearing the R142Q mutation had normal catalytic activity per molecule, but markedly impaired binding to a CD26+ ADA-deficient human T cell line. Reduced CD26 binding was also found with ADA from red cells and T cells of a healthy individual whose only expressed ADA has the R142Q mutation. Conversely, ADA with the E217K active site mutation, the only ADA expressed by a severely immunodeficient patient, showed normal CD26 binding. These findings argue that ADA binding to CD26 is not essential for immune function in humans.


2007 ◽  
Vol 17 (6) ◽  
pp. 1765-1768 ◽  
Author(s):  
Scott M. Sheehan ◽  
Hans-Juergen Mest ◽  
Brian M. Watson ◽  
Valentine J. Klimkowski ◽  
David E. Timm ◽  
...  

Biochemistry ◽  
1992 ◽  
Vol 31 (9) ◽  
pp. 2582-2587 ◽  
Author(s):  
Shigenori Ogata ◽  
Yoshio Misumi ◽  
Emiko Tsuji ◽  
Noboru Takami ◽  
Kimimitsu Oda ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document